Abstract
Objectives Previous observational studies have shown that vitiligo usually co-manifests with a variety of dysglycemic diseases, such as Type 1 diabetes mellitus(T1DM) and Type 2 diabetes mellitus(T2DM). Mendelian randomization analysis was performed to further evaluate the causal association between fasting plasma glucose, glycosylated hemoglobin(HbA1c),T1DM,T2DM and vitiligo.
Methods We used aggregated genome-wide association data from the (Integrative Epidemiology Unit) IEU online database of European adults vitiligo; Glycated hemoglobin (HbA1c) data were from (IEU). Fasting blood glucose data were obtained from the European Bioinformatics Institute(EBI). T1DM and T2DM data were from FinnGen(FINN).
We used bidirectional two-sample and multivariate Mendelian randomization analyses to test whether dysglycemic measures (fasting blood glucose, HbA1c), diabetes-related measures (T1DM, T2DM) are causatively associated with vitiligo. IVW method was used as the main test method, MR-Egger, Weighted mode and Weighted median were used as supplementary methods.
Results We found no statistically significant evidence to support a causal association between dysglycemic traits and vitiligo, but in the correlation analysis of diabetic traits, our data supported a positive causal association between T1DM and vitiligo (p=0.018; 95%OR:1.000(1.000-1.000)); In the follow-up multivariate MR Analysis, our results still supported this conclusion (p=0.016, 95% OR= 1.000(1.000-1.000)), and suggested that Hba1c was not a mediator of T1DM affecting the pathogenesis of vitiligo. No reverse causality was found in any of the reverse MR Analyses of dysglycemic traits and diabetic traits.
Conclusions Our findings support that T1DM is a risk factor for the development of vitiligo, and this conclusion may explain why the co-presentation of T1DM and vitiligo is often seen in observational studies. Clinical use of measures related to T1DM may be a new idea for the prevention or treatment of vitiligo.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Natural Science Foundation of China(grant nos. 82074443), and by the Program of Science and Technology Department of Sichuan Province (2021ZYD0089).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We used aggregated genome-wide association data from the (Integrative Epidemiology Unit) IEU online database of European adults vitiligo; Glycated hemoglobin (HbA1c) data were from (IEU). Fasting blood glucose data were obtained from the European Bioinformatics Institute(EBI). T1DM and T2DM data were from FinnGen(FINN).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability Statement
Publicly available datasets were analyzed in this study. This data can be found here: All GWAS data used in this study are available in the IEU open GWAS project (https://gwas.mrcieu.ac.uk/). Detailed data on vitiligo are available in the GWAS through the UK Biobank data(http://www.nealelab.is/uk-biobank/c). Summary statistics for T1DM and T2DM are from the FinnGen Consortium (https://r8.finngen.fi).
